Moldávia - romeno - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ncpc international corp. - ceftazidimum - pulbere pentru soluţie injectabilă/perfuzabilă - 2 g

Moldávia - romeno - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ncpc international corp. - ceftazidimum - pulbere pentru soluţie injectabilă/perfuzabilă - 0,5 g

Moldávia - romeno - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ncpc international corp. - ceftazidimum - pulbere pentru soluţie injectabilă/perfuzabilă - 1 g

Moldávia - romeno - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ncpc international corp. - ceftriaxonum - pulbere pentru soluţie injectabilă/perfuzabilă - 0,5 g

União Europeia - romeno - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , terapie triplă) ca adjuvant la dietă și exercițiu fizic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin și o sulfoniluree. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

União Europeia - romeno - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuclide imaging - produse radiofarmaceutice terapeutice - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

União Europeia - romeno - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , terapie triplă) ca adjuvant la dietă și exercițiu fizic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin și o sulfoniluree. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

União Europeia - romeno - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , terapie triplă) ca adjuvant la dietă și exercițiu fizic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin și o sulfoniluree. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Moldávia - romeno - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck selbstmedikation gmbh - oxymetazolinum - picături nazale, soluţie - 0,25 mg/ml

Moldávia - romeno - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck selbstmedikation gmbh - oxymetazolinum - picături nazale, soluţie - 0,5 mg/ml